drugset
drugset / Trial / NCT03657030

Study of CVN424 in Healthy Subjects

NCT03657030 ↗

Phase 1 Completed 64 enrolled Cerevance Beta, Inc.
RandomizedSequentialQuadruple-blindOther

Summary

This is a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose ascending study in healthy subjects.

Timeline

Start
2018-09-18
Primary completion
2019-03-01
Completion
2019-05-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator SOLENGEPRAS Small molecule 1 mg —
Comparator SOLENGEPRAS Small molecule 5 mg —
Comparator SOLENGEPRAS Small molecule 25 mg —
Comparator SOLENGEPRAS Small molecule 75 mg —
Comparator SOLENGEPRAS Small molecule 150 mg —
Comparator SOLENGEPRAS Small molecule 225 mg —

Indications

No indication recorded.